Can PEGPH20 enhance efficacy of eribulin mesylate in high-hyaluronan metastatic breast cancer?
The primary endpoint of the Phase Ib portion of the study is to determine the recommended dosage of the eribulin and PEGPH20 combination.1 Safety and efficacy data will also be reported.1 The primary endpoint of the Phase II study is overall response rate.1 Secondary endpoints will include progression-free and overall survival. The study includes only patients with high hyaluronan tumours in order to target a treatment-sensitive population.1
Eribulin is indicated in the European Union for the treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.
This article and interview have been initiated and funded by Eisai.